Arix Bioscience portofolio company Artios announces collaboration with Novartis to create next generation DDR cancer therapies

  • Artios to receive $20 million up-front payment in addition to near term research funding to support the collaboration.
  • Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.

LONDON, 07 April 2021: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’ Radioligand Therapies (RLT).

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...